BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020

Post Reprod Health. 2021 Mar;27(1):49-55. doi: 10.1177/2053369120983154. Epub 2021 Jan 17.

Authors

Haitham Hamoda¹, Susan R Davis², Antonio Cano³, Edward Morris⁴, Sonia Davison⁵, Nicholas Panay⁶, Mary A Lumsden⁷, Tim Hillard⁸, Tommaso Simoncini²

Affiliations

¹ King's College Hospital, London, UK.
² International Menopause Society Truro, Cornwall, UK.
³ European Menopause and Andropause Society, Berlin, Germany.
⁴ Norfolk & Norwich University Hospital, Norwich, UK.
⁵ Australasian Menopause Society, Healesville, Australia.
⁶ Queen Charlotte's and Chelsea & Westminster Hospitals, London, UK.
⁷ Glasgow Royal Infirmary, University of Glasgow, Glasgow, UK.
⁸ Poole Hospital NHS Foundation Trust, Poole Hospital, Poole, UK.

PMID: 33459135
DOI: 10.1177/2053369120983154

No abstract available

Publication types

Letter

MeSH terms

Breast Neoplasms* / chemically induced
Breast Neoplasms* / epidemiology
Female
Hormone Replacement Therapy / adverse effects
Humans
Menopause
Pharmacovigilance*
Risk Assessment